Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Pharmacol Biochem Behav. 2011 Mar 5;98(4):493–502. doi: 10.1016/j.pbb.2011.02.024

Figure 4.

Figure 4

(a) Effects of cannabilactone and aminoalkylindole cannabinoid agonists on tail flick antinociception and hypothermia. WIN55,212-2 (WIN-2; 5 mg/kg i.p.) produced CB1-mediated antinociception in the tail flick test. This effect was blocked by the CB1 antagonist SR141716 (SR1; 6 mg/kg i.p.). Neither (R,S)-AM1241 (1 mg/kg i.p.) nor AM1710 (0.1, 5, and 10 mg/kg i.p.) produced antinociception in the tail flick test. (b) WIN55,212-2 (5 mg/kg i.p.) decreased rectal temperature relative to baseline through a CB1 mechanism; this effect was blocked by SR141716 (SR1; 6 mg/kg i.p.). Neither (R,S)-AM1241 (1 mg/kg i.p.) nor AM1710 (0.1, 5, and 10 mg/kg i.p.) altered rectal temperature. **P < 0.01, ***P < 0.001 vs. DMSO control condition, ⊥P < 0.05, ⊥⊥P < 0.01, ⊥⊥ ⊥P < 0.001 vs. all drug conditions, ×P < 0.05 vs. AM1710 (10 mg/kg i.p.), WIN-2 + SR1, and (R,S)-AM1241 (1 mg/kg i.p.), #P < 0.05 vs. AM1710 (10 mg/kg i.p.) (ANOVA; Dunnett and Tukey post hoc tests). N = 6–7 per group.